Shares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT.Vimseltinib is expected to make significant progress in the ...
Source LinkShares of Deciphera Pharmaceuticals, Inc. have rallied 40% since October after positive trial data for vimseltinib in the treatment of TGCT.Vimseltinib is expected to make significant progress in the ...
Source Link
Comments